Utah Medical Products Inc (UTMD)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $206.03M
Last updated: Nov 17, 2026 at 4:10 PM ET
Utah Medical Products Inc (UTMD) Statistics
Utah Medical Products (UTMD) has a market cap of $206.03M and an enterprise value of $121.01M. It holds $85.02M more cash than debt, 41.27% of its market cap. It kept 30.48% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 41.27% below the market cap, as cash exceeds debt.
| Market Cap | $206.03M |
|---|---|
| Enterprise Value | $121.01M |
| Latest price (Nov 17, 2026) | $72.02 |
Key Dates
The next earnings report is expected on Jan 27, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Dec 17, 2026.
| Next Earnings Date | Jan 27, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 22, 2026 |
| Next Ex-Dividend Date | Dec 17, 2026 |
| Next Payment Date | Jan 5, 2027 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 6.6x and 1.9x. Its year-end P/E ranged from 15.6x to 28.0x from 2016 to 2025.
| P/E Ratio | 21.6x |
|---|---|
| P/S Ratio | 6.6x |
| P/B Ratio | 1.9x |
| P/TBV Ratio | 2.2x |
| P/FCF Ratio | 21.1x |
| P/OCF Ratio | 18.0x |
Enterprise Valuation
Counting debt and cash, the company is valued at 11.9x EBITDA and 13.3x free cash flow.
| EV / Earnings | 11.4x |
|---|---|
| EV / Sales | 3.5x |
| EV / EBITDA | 11.9x |
| EV / EBIT | 9.3x |
| EV / FCF | 13.3x |
Price Statistics
The stock is up 31.37% over 52 weeks and trades 1.42% below its 50-day average.
| Beta (1Y) | 0.25 |
|---|---|
| 52-Week Change | +31.37% |
| 1-Month Change | -3.39% |
| 3-Month Change | +0.28% |
| 6-Month Change | +13.53% |
| 5-Year Change | -29.70% |
| 10-Year Change | +9.53% |
| Total Return (1Y) | +33.63% |
| Total Return (3Y CAGR) | -3.81% |
| Total Return (5Y CAGR) | -7.06% |
| Return vs SPY (1Y) | +21.61% |
| Max Drawdown (1Y) | -13.24% |
| Max Drawdown (3Y) | -38.54% |
| Sharpe Ratio (1Y) | 1.00 |
| Correlation with SPY (1Y) | 0.12 |
| 50-Day Average | $73.06 |
| 200-Day Average | $68.37 |
| 52-Week Range | $52.65 to $76.89 |
| RSI (14 Days) | 48.2 |
| Average Volume (20 Days) | 32.85K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 21.23x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 21.23x |
|---|---|
| Quick Ratio | 19.00x |
| Debt / Equity | 0.00x |
| Debt / EBITDA | 0.01x |
| Debt / FCF | 0.02x |
Returns and Efficiency
Return on invested capital is 6.74% over the last 12 months, against a 5-year average of 7.55%.
| Return on Equity (ROE) | 8.63% |
|---|---|
| Return on Assets (ROA) | 8.28% |
| Return on Invested Capital (ROIC) | 6.74% |
| Return on Capital Employed (ROCE) | 10.48% |
| ROE (5Y Average) | 12.49% |
| ROA (5Y Average) | 11.78% |
| ROIC (5Y Average) | 7.55% |
| Asset Turnover | 0.28x |
| Inventory Turnover | 1.51x |
| Receivables Turnover | 9.28x |
| Cash Conversion Cycle | 250 days |
Taxes
Income tax took 17.98% of pretax income over the last 12 months.
| Income Tax (TTM) | $2.33M |
|---|---|
| Effective Tax Rate | 17.98% |
Scores
UTMD has an Altman Z-Score of 29.19, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 29.19 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $34.92M over the last 12 months is down 9.62% from the 12 months before.
| Revenue | $34.92M |
|---|---|
| Revenue Growth (YoY) | -9.62% |
| Gross Profit | $19.61M |
| Operating Income | $10.45M |
| Pretax Income | $12.97M |
| Net Income | $10.64M |
| EBITDA | $14.92M |
| EBIT | $12.97M |
| Reported EPS (TTM) | $3.34 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 95.94% of the $128.50M in total assets.
| Cash and Equivalents | $85.20M |
|---|---|
| Total Debt | $180.00K |
| Net Cash | $85.02M |
| Net Cash Per Share | $26.74 |
| Working Capital | $95.89M |
| Shareholder Equity | $123.28M |
| Book Value Per Share | $38.77 |
| Tangible Book Value | $105.43M |
| Tangible Book Per Share | $33.16 |
| Total Assets | $128.50M |
| Total Liabilities | $5.22M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $609.00K of capital spending, operating cash flow left $10.86M of free cash flow.
| Operating Cash Flow | $11.47M |
|---|---|
| Capital Expenditures | $609.00K |
| Free Cash Flow | $10.86M |
| FCF Per Share | $3.81 |
| Depreciation and Amortization | $1.96M |
| Dividends Paid | $3.94M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 29.93%, against a 5-year average of 34.52%.
| Gross Margin | 56.17% |
|---|---|
| Operating Margin | 29.93% |
| Pretax Margin | 37.16% |
| Net Margin | 30.48% |
| EBITDA Margin | 42.72% |
| EBIT Margin | 37.16% |
| FCF Margin | 31.10% |
| Gross Margin (5Y Average) | 60.11% |
| Operating Margin (5Y Average) | 34.52% |
| Net Margin (5Y Average) | 31.60% |
Growth
Revenue fell 9.68% a year over 3 years, and EPS 8.30% a year.
| Revenue Growth (3Y CAGR) | -9.68% |
|---|---|
| Revenue Growth (5Y CAGR) | -1.80% |
| EPS Growth (3Y CAGR) | -8.30% |
| EPS Growth (5Y CAGR) | -8.25% |
| FCF Growth (3Y CAGR) | -11.03% |
| FCF Growth (5Y CAGR) | -5.77% |
| Operating Income Growth (3Y CAGR) | -16.79% |
| Book Value Per Share Growth (2Y CAGR) | +2.70% |
| Tangible Book Per Share Growth (2Y CAGR) | +3.92% |
Dividends and Yields
UTMD pays out 34.38% of earnings as dividends.
| Dividend Per Share (Annual) | $1.24 |
|---|---|
| Dividend Yield | 1.72% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +1.69% |
| Dividend Growth (5Y CAGR) | +1.72% |
| Payout Ratio | 34.38% |
| FCF Payout Ratio | 36.28% |
| Earnings Yield | 4.63% |
| FCF Yield | 4.74% |
| Buyback Yield | 0.83% |
| Shareholder Yield | 2.55% |
Peer Position
Against 6 similar companies, UTMD has the 4th highest P/E.
P/E RatioPeer median 21.4x
P/S RatioPeer median 2.3x
ROICPeer median 8.86%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +8.63%
Dividend YieldPeer median 0.00%
| P/E Ratio | 21.6x vs 21.4x median |
|---|---|
| P/S Ratio | 6.6x vs 2.3x median |
| ROIC | 6.74% vs 8.86% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -9.62% vs +8.63% median |
| Dividend Yield | 1.72% vs 0.00% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About UTMD
What is UTMD's market cap?
Utah Medical Products has a market cap of $206.03M. Its enterprise value, which adds debt and subtracts cash, is $121.01M.
What is UTMD's P/E ratio?
Utah Medical Products has a trailing P/E ratio of 21.6x.
How many shares of UTMD are outstanding?
Utah Medical Products has 3.18M shares outstanding. The count is down 0.84% from a year earlier.
Does UTMD pay a dividend?
Yes. Utah Medical Products pays $1.24 a share a year, a dividend yield of 1.72%.
How much debt does UTMD have?
Utah Medical Products has $180.00K of total debt and $85.20M of cash and equivalents, a net cash position of $85.02M.
UTMD pages: Overview, Dividends, Charting, Earnings, Financials, Statistics, Valuation, Competitors